Bio Path Holdings

Bio Path Holdings P/CF

Delisted·Sep 10, 2026

The P/CF (Price-to-Cash-Flow Ratio) of Bio Path Holdings (BPTH) as of Oct 17, 2026 is -0.05. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was -0.05 — a change of 9.08% (lower).

P/CF

-0.05

YoY

9.08%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of Bio Path Holdings is 2024 -0.05 . P/CF (Price-to-Cash-Flow Ratio) of Bio Path Holdings was 2023 -0.05 . It decreases by 9.08% lower compared to the previous year.

The Bio Path Holdings P/CF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/CF
Date
P/CF
Jan 1, 2017
-0.07 USD
Jan 1, 2018
-0.09 USD
Jan 1, 2019
-0.06 USD
Jan 1, 2020
-0.05 USD
Jan 1, 2021
-0.05 USD
Jan 1, 2022
-0.04 USD
Jan 1, 2023
-0.05 USD
Jan 1, 2024
-0.05 USD
The Bio Path Holdings P/CF history
YEARP/CFYoY
-0.05+9.08%
-0.05+30.93%
-0.04-34.34%
-0.05+10.52%
-0.05-23.71%
-0.06-26.76%
-0.09+29.93%
-0.07+2.40%
-0.07-38.58%
-0.11-23.72%
-0.14—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio Path Holdings Stock analysis

What does Bio Path Holdings do? Bio Path Holdings Inc, listed under ticker BPTH, is a biotechnology company headquartered in Bellaire, Texas. It focuses on developing therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). The company has 10 employees and went public on January 11, 2006. Its technology, DNAbilize, delivers antisense drugs via a DNA backbone modification to protect against enzymatic destruction, enabling systemic distribution to target proteins in blood diseases and solid organs. The company has three antisense drug candidates in development for over five cancer disease indications. Bio Path Holdings is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio Path Holdings stock

P/CF (Price-to-Cash-Flow Ratio) of Bio Path Holdings is -0.05 in 2024.

P/CF (Price-to-Cash-Flow Ratio) of Bio Path Holdings changed from -0.05 to -0.05, representing a 9.08% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) Bio Path Holdings since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s Bio Path Holdings with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Bio Path Holdings

All Key Metrics — Bio Path Holdings